Total Knee Arthroplasty: 16 US centers
- 139 patients who received a TKA, with 70 receiving EXPAREL and 69 who did not
- Phase 4 clinical trial
- Both treatments were well tolerated, with most adverse events mild or moderate. One patient in each group experienced a serious adverse event, with both events deemed unrelated to the study medication
Clinical and Economic Outcomes
In patients who received EXPAREL for analgesia
better pain control
12 to 48 hours
reduction in opioid
use 0 to 48 hours
free of opioids
at 72 hours
*Pain measured using visual analog scale.
†The clinical benefit of the decrease in opioid consumption was not demonstrated in the clinical trials.
‡Compared with 0% of patients who received bupivacaine HCl alone.
TKA, total knee arthroplasty.